Teva Pharmaceutical Industries Limited (NYSE:TEVA) vs. Its Peers Head-To-Head Review

Teva Pharmaceutical Industries Limited (NYSE: TEVA) is one of 115 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Teva Pharmaceutical Industries Limited to similar businesses based on the strength of its dividends, institutional ownership, earnings, risk, analyst recommendations, profitability and valuation.

Dividends

Teva Pharmaceutical Industries Limited pays an annual dividend of $0.94 per share and has a dividend yield of 6.4%. Teva Pharmaceutical Industries Limited pays out -15.4% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.4% and pay out 70.7% of their earnings in the form of a dividend. Teva Pharmaceutical Industries Limited is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.

Volatility & Risk

Teva Pharmaceutical Industries Limited has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries Limited’s competitors have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Teva Pharmaceutical Industries Limited and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries Limited 4 16 5 0 2.04
Teva Pharmaceutical Industries Limited Competitors 818 3681 6700 181 2.55

Teva Pharmaceutical Industries Limited currently has a consensus price target of $27.70, indicating a potential upside of 87.95%. As a group, “Pharmaceuticals” companies have a potential upside of 21.62%. Given Teva Pharmaceutical Industries Limited’s higher possible upside, research analysts clearly believe Teva Pharmaceutical Industries Limited is more favorable than its competitors.

Valuation and Earnings

This table compares Teva Pharmaceutical Industries Limited and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Teva Pharmaceutical Industries Limited $23.37 billion $7.42 billion -2.41
Teva Pharmaceutical Industries Limited Competitors $8.08 billion $2.64 billion -0.23

Teva Pharmaceutical Industries Limited has higher revenue and earnings than its competitors. Teva Pharmaceutical Industries Limited is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

56.8% of Teva Pharmaceutical Industries Limited shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.1% of Teva Pharmaceutical Industries Limited shares are owned by company insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Teva Pharmaceutical Industries Limited and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries Limited -25.18% 15.96% 5.31%
Teva Pharmaceutical Industries Limited Competitors -2,882.39% -67.85% -8.80%

Summary

Teva Pharmaceutical Industries Limited beats its competitors on 9 of the 14 factors compared.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cora Becomes New Manager for Boston Red Sox
Alex Cora Becomes New Manager for Boston Red Sox
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends


Leave a Reply

 
© 2006-2017 BBNS.